Anti-tumour effect of tocilizumab for osteosarcoma cell lines. Issue 11 (1st November 2020)

• Record Type: Journal Article
• Authors: Hagi, Tomohito; Nakamura, Tomoki; Kita, Kouji; Iino, Takahiro; Asanuma, Kunihiro; Sudo, Akihiro
• Is Part Of: Bone & joint research. Volume 9:Issue 11(2020)
• Page Start: 821
• Page End: 826
• Publication Date: 2020-11-01
• Subjects: Osteosarcoma -- Tocilizumab -- Anti-tumour effect -- Interleukin-6 -- Interleukin-6 receptor; Musculoskeletal system -- Periodicals; 573.705
• DOI: 10.1302/2046-3758.911.BJR-2020-0123.R1
• Languages: English
• ISSNs: 2046-3758

Abstract

Abstract : Aims: Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines. Methods: We used the 143B, HOS, and Saos-2 human OS cell lines. We first analyzed the IL-6 gene expression and IL-6Rα protein expression in OS cells using reverse transcription real time quantitative-polymerase chain reaction (RT-qPCR) analysis and western blotting, respectively. We also assessed the effect of tocilizumab on OS cells using proliferation and invasion assay. Results: The OS cell lines 143B, HOS, and Saos-2 expressed IL-6R. Recombinant human IL-6 treatment increased proliferation of 143B and HOS cells. Tocilizumab treatment decreased proliferation and invasion of 143B, HOS, and Saos-2. Conclusion: In conclusion, we confirmed the production of IL-6 and the expression of IL-6R in OS cells and demonstrated that tocilizumab inhibits proliferation and invasion in OS cells. Cite this article: Bone Joint Res 2020;9(11):821–826.